Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic Implications.
BRAF inhibitor
BRAF p.V600E mutation
CDKN2A
MAPK-induced gliomas
MEK inhibitor
driver
oncogene-induced senescence
passenger molecular alterations
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Feb 2023
16 Feb 2023
Historique:
received:
24
10
2022
revised:
25
01
2023
accepted:
04
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Over the last few decades, deciphering the alteration of molecular pathways in brain tumors has led to impressive changes in diagnostic refinement. Among the molecular abnormalities triggering and/or driving gliomas, alterations in the MAPK pathway reign supreme in the pediatric population, as it is encountered in almost all low-grade pediatric gliomas. Activating abnormalities in the MAPK pathway are also present in both pediatric and adult high-grade gliomas. Across those alterations,
Identifiants
pubmed: 36831610
pii: cancers15041268
doi: 10.3390/cancers15041268
pmc: PMC9954401
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Neurooncol. 2020 Oct;150(1):5-15
pubmed: 32399739
Genes Dev. 2013 Apr 15;27(8):900-15
pubmed: 23599344
J Neurooncol. 2016 Feb;126(3):385-93
pubmed: 26384810
JAMA Oncol. 2017 Feb 01;3(2):202-208
pubmed: 27581851
Oncotarget. 2016 Jan 26;7(4):5030-41
pubmed: 26452024
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
Clin Cancer Res. 2021 Nov 15;27(22):6197-6208
pubmed: 34433654
Sci Rep. 2021 Oct 8;11(1):19999
pubmed: 34625582
Mech Ageing Dev. 2020 Apr;187:111229
pubmed: 32171687
Nat Commun. 2018 Feb 8;9(1):579
pubmed: 29422527
J Cell Mol Med. 2020 May;24(9):5135-5145
pubmed: 32277580
Genes Dev. 2012 May 15;26(10):1055-69
pubmed: 22549727
Proc Natl Acad Sci U S A. 2021 Mar 16;118(11):
pubmed: 33836600
Acta Neuropathol. 2013 Dec;126(6):907-15
pubmed: 24154961
Cell. 1997 Mar 7;88(5):593-602
pubmed: 9054499
Biochem Soc Trans. 2021 Feb 26;49(1):237-251
pubmed: 33367512
Oncogene. 2011 Aug 11;30(32):3477-88
pubmed: 21577205
Nat Commun. 2021 Sep 20;12(1):5531
pubmed: 34545084
Neuro Oncol. 2022 May 4;24(5):741-754
pubmed: 34865163
Nature. 2005 Aug 4;436(7051):720-4
pubmed: 16079850
Int J Mol Med. 2009 Jan;23(1):17-31
pubmed: 19082503
Neuro Oncol. 2022 Apr 1;24(4):528-540
pubmed: 34718782
JCO Precis Oncol. 2020 May 20;4:
pubmed: 32923898
Cancer Res. 2018 Jun 1;78(11):2966-2977
pubmed: 29545335
Acta Neuropathol. 2018 Aug;136(2):273-291
pubmed: 29564591
J Clin Oncol. 2016 Jul 1;34(19):2206-11
pubmed: 27001570
Brain Pathol. 2012 Nov;22(6):834-40
pubmed: 22568401
Brain Pathol. 2014 Jan;24(1):52-66
pubmed: 23941441
J Neuropathol Exp Neurol. 2021 Sep 27;80(11):1052–1059
pubmed: 34580728
J Neurooncol. 2019 Aug;144(1):137-146
pubmed: 31214915
Cancer Cell. 2004 Oct;6(4):313-9
pubmed: 15488754
Cancer Cell. 2018 May 14;33(5):829-842.e5
pubmed: 29763623
Cancer Cell. 2017 Oct 9;32(4):520-537.e5
pubmed: 28966033
J Neuropathol Exp Neurol. 2022 Jul 19;81(8):650-657
pubmed: 35703914
Brain Pathol. 2019 Jan;29(1):85-96
pubmed: 30051528
Clin Cancer Res. 2011 Jun 1;17(11):3590-9
pubmed: 21636552
Neuro Oncol. 2013 Dec;15(12):1604-14
pubmed: 24203892
J Clin Oncol. 2018 Dec 10;36(35):3477-3484
pubmed: 30351999
Lancet Oncol. 2022 Jan;23(1):53-64
pubmed: 34838156
Brain Pathol. 2020 Jul;30(4):844-856
pubmed: 32307792
J Neuropathol Exp Neurol. 2021 Dec 29;80(12):1099-1107
pubmed: 34850053
Neuro Oncol. 2012 Sep;14(9):1146-52
pubmed: 22753230
Front Oncol. 2015 Mar 03;5:54
pubmed: 25785246
Oncogene. 2017 Nov 9;36(45):6325-6335
pubmed: 28745322
Clin Cancer Res. 2011 Jul 15;17(14):4650-60
pubmed: 21610151
Cancer Res. 2010 Jan 15;70(2):512-9
pubmed: 20068183
Oncogene. 2019 Apr;38(16):2994-3002
pubmed: 30575814
Brain Tumor Pathol. 2019 Jul;36(3):103-111
pubmed: 30972500
Ther Adv Med Oncol. 2019 Jun 18;11:1758835919856494
pubmed: 31244912
Cancer Lett. 2022 Oct 10;546:215850
pubmed: 35926818
Cancers (Basel). 2019 Aug 28;11(9):
pubmed: 31466300
J Clin Oncol. 2015 Mar 20;33(9):1015-22
pubmed: 25667294
J Neuropathol Exp Neurol. 2013 Jan;72(1):2-7
pubmed: 23242278
Acta Neuropathol Commun. 2018 Mar 15;6(1):24
pubmed: 29544532
Cancer Cell. 2020 Apr 13;37(4):569-583.e5
pubmed: 32289278
Brain Pathol. 2021 Jan;31(1):20-32
pubmed: 32619305
J Clin Oncol. 2017 Sep 1;35(25):2934-2941
pubmed: 28727518
Neuro Oncol. 2022 Nov 2;24(11):1964-1975
pubmed: 35397478
CNS Oncol. 2017 Oct;6(4):291-296
pubmed: 28984141
Pediatr Blood Cancer. 2015 Oct;62(10):1768-74
pubmed: 25981859
Pediatr Blood Cancer. 2022 Aug;69(8):e29575
pubmed: 35373885
Brain Pathol. 2019 Jan;29(1):126-140
pubmed: 30192422
Cancer Cell. 2013 Nov 11;24(5):660-72
pubmed: 24183680
Brain Pathol. 2018 Sep;28(5):656-662
pubmed: 28990704
Neurology. 2017 Mar 28;88(13):1291-1293
pubmed: 28235815
Acta Neuropathol. 2019 Apr;137(4):683-687
pubmed: 30848347
Cancer Cell. 2015 Sep 14;28(3):370-83
pubmed: 26343582
Neuro Oncol. 2022 Dec 1;24(12):2015-2034
pubmed: 35908833
Cancer Discov. 2018 Sep;8(9):1130-1141
pubmed: 29880583
Acta Neuropathol Commun. 2018 Jun 7;6(1):47
pubmed: 29880043
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6
pubmed: 23530248
J Neurooncol. 2020 Sep;149(3):463-472
pubmed: 33009979